Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Frequently asked questions
What sector does Novavax Inc (NVV1) operate in?
Novavax Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Novavax Inc (NVV1) current stock price?
As of the latest data, Novavax Inc stock price is €8.34, with a previous close of €8.57. Novavax Inc lost -€0.23 in the last trading session, representing a -2.68% loss.
What is Novavax Inc (NVV1) current market capitalization?
Novavax Inc market cap is approximately 1.38 billion.
What is Novavax Inc (NVV1) Earnings Per Share (EPS)?
The trailing EPS is -€1.35.
What is Novavax Inc (NVV1) EBITDA?
Novavax Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -37.59 million.
Does Novavax Inc (NVV1) pay dividends?
No. Novavax Inc does not pay a dividend.
When is Novavax Inc (NVV1) next earnings report?
Novavax Inc is expected to release its next earnings report on September 30, 2026.
What is Novavax Inc (NVV1) beta (volatility) score?
Novavax Inc has a beta of 2.435, indicating very high volatility compared to the market.